The landscape of plaque psoriasis treatment is on the cusp of a significant shift with the U.S. Food and Drug Administration’s (FDA) approval of Johnson & Johnson’s (J&J) Icotyde (icotrokinra). This novel oral peptide therapy marks a pivotal moment, representing the first-ever oral peptide approved for this chronic autoimmune condition in the United States. Analysts are forecasting a blockbuster future for Icotyde, projecting global sales to reach $4.4 billion by 2032, positioning it as a formidable contender against AbbVie’s highly successful injectable biologic, Skyrizi.
A New Era for Oral Therapies in Psoriasis
The FDA’s green light for Icotyde signifies a new therapeutic avenue for adults and pediatric patients aged 12 and older suffering from moderate-to-severe plaque psoriasis. This approval is specifically targeted at individuals who are candidates for systemic therapy or phototherapy, broadening the potential patient pool for this innovative treatment. Psoriasis, a condition affecting over 8 million people in the U.S., is characterized by the rapid multiplication of skin cells, leading to the development of thick, itchy, and scaly patches. Icotyde’s mechanism of action involves the inhibition of interleukin-23 (IL-23), a key protein implicated in the inflammatory pathways that drive psoriasis.
The approval of Icotyde is the culmination of extensive clinical trials, with its efficacy demonstrated across four Phase III studies involving approximately 2,500 patients. These trials reportedly met all primary efficacy endpoints, showcasing Icotyde’s ability to significantly improve skin clarity and reduce disease severity. Notably, Icotyde has also demonstrated superiority in head-to-head trials against Bristol Myers Squibb’s (BMS) Sotyktu (deucravacitinib), another oral therapy for plaque psoriasis. This direct comparative data is crucial in a competitive market, suggesting a strong clinical profile for J&J’s new entrant.
Challenging the Giants: Skyrizi and Sotyktu
The current U.S. plaque psoriasis market is largely dominated by two key players: AbbVie’s Skyrizi and BMS’s Sotyktu. Skyrizi, a blockbuster injectable monoclonal antibody, also targets IL-23 and has established itself as a significant revenue driver for AbbVie, particularly as the company navigates the loss of exclusivity for its former flagship drug, Humira. Sotyktu, on the other hand, is an oral small molecule inhibitor that targets tyrosine kinase 2 (TYK2).
Icotyde’s unique position as the only oral peptide targeting IL-23 in the U.S. market provides it with a distinct competitive edge. Stephanie Ngan, an analyst at GlobalData, highlighted Icotyde’s "biologic-like efficacy delivered in a once-daily oral pill" as its strongest selling point. She further elaborated that its macrocyclic design likely contributes to this potent efficacy, offering a compelling alternative to existing oral options. The direct superiority demonstrated against Sotyktu is particularly noteworthy, suggesting Icotyde could capture a significant share of the market currently held by that drug.
However, Ngan also pointed out potential challenges, noting that "Icotyde does entail a higher treatment burden and daily commitment than biologics such as Skyrizi, which requires only 4 doses per year." This comparison underscores the ongoing trade-offs patients and physicians consider when selecting psoriasis treatments, balancing efficacy with convenience and adherence.
A Strategic Succession and Expanding Pipeline
The introduction of Icotyde is strategically timed within J&J’s broader portfolio. The drug is expected to succeed J&J’s own Stelara (ustekinumab), an IL-23 inhibitor that previously held a significant market position but lost patent exclusivity in early 2025. J&J also markets Tremfya (guselkumab), another IL-23 inhibitor, though it is administered via injection, similar to Skyrizi. Icotyde, therefore, represents a significant advancement in J&J’s oral treatment offerings for psoriasis.
The National Psoriasis Foundation has expressed optimism regarding the approval. Leah Howard, CEO of the organization, stated, "The approval of a novel systemic therapy changes the conversation about treatment options for our community." This sentiment reflects the ongoing need for diverse and effective therapeutic choices for individuals living with chronic psoriasis.
Beyond plaque psoriasis, J&J is actively exploring further indications for its IL-23 inhibitor technology. Clinical trials are underway for active psoriatic arthritis (ICONIC-PsA 1 and ICONIC-PsA 2), as well as for moderately-to-severely active ulcerative colitis (ICONIC-UC) and Crohn’s disease (ICONIC-CD). This pipeline expansion signals J&J’s commitment to leveraging its IL-23 inhibition platform across a range of inflammatory conditions.
Market Projections and Competitive Dynamics
The optimistic outlook for Icotyde is further supported by market analysis. GlobalData forecasts that by 2032, the drug’s global sales will reach an impressive $4.4 billion. This projection is bolstered by the drug’s simultaneous approval for both adult and adolescent populations. Ngan commented that this "casts a wider net for early uptake across a broader patient population" compared to traditional phased approvals.
The acquisition of global rights to Icotyde by J&J from Protagonist Therapeutics in 2017, through a deal potentially worth up to $990 million, underscores the significant strategic value placed on this therapy. Reports from late 2025 suggested ongoing discussions regarding a potential acquisition of Protagonist Therapeutics by J&J, although no public updates have been released since.
Despite the promising outlook for Icotyde, displacing Skyrizi’s established dominance will require substantial effort. Skyrizi’s broad range of immunology indications and strong adoption in inflammatory bowel disease (IBD) have made it a major revenue generator for AbbVie. In 2025, Skyrizi achieved global sales of $17.6 billion, exceeding growth expectations. This success has been instrumental in reducing AbbVie’s reliance on Humira, which was once the world’s best-selling drug. The established patient base, physician familiarity, and extensive clinical experience with Skyrizi present a formidable competitive barrier for any new entrant.
The Evolving Treatment Paradigm
The introduction of Icotyde represents a significant evolution in the treatment paradigm for plaque psoriasis. For decades, treatment options were limited to topical therapies, phototherapy, and systemic immunosuppressants with significant side effect profiles. The advent of biologic therapies, which precisely target inflammatory pathways, revolutionized patient care. However, the requirement for injections presented a barrier for some patients.
The development of oral small molecule inhibitors like Sotyktu and now oral peptides like Icotyde offers a more convenient administration route while maintaining high levels of efficacy, comparable to injectables. This shift towards oral therapies is a key trend in dermatology and immunology, driven by patient preference for ease of use and improved adherence.
The competitive interplay between Icotyde, Skyrizi, and Sotyktu will likely lead to more personalized treatment approaches. Physicians will have a wider array of options to tailor therapies based on individual patient needs, disease severity, comorbidities, and preferences regarding administration. The head-to-head superiority data of Icotyde over Sotyktu is particularly impactful, suggesting a potential re-evaluation of treatment algorithms for patients currently on or considering TYK2 inhibitors.
Future Outlook and Unanswered Questions
The long-term success of Icotyde will depend on several factors, including its safety profile in real-world settings, its ability to demonstrate sustained efficacy over time, and its market access and reimbursement landscape. As J&J expands Icotyde’s application to other inflammatory conditions, its overall impact on the pharmaceutical market and patient care will become even more pronounced.
The development of Icotyde by Protagonist Therapeutics and its subsequent licensing to J&J highlights the ongoing innovation in drug discovery and development. The company’s proprietary peptide technology has proven capable of generating molecules with high potency and specificity, offering a new platform for drug development beyond traditional small molecules and biologics.
As the pharmaceutical industry continues to evolve, the competition in the plaque psoriasis market serves as a microcosm of broader trends: the pursuit of targeted therapies, the drive for convenient administration routes, and the relentless innovation aimed at improving the lives of patients with chronic and debilitating diseases. The arrival of Icotyde is a testament to this progress, promising a new chapter in the management of plaque psoriasis and potentially setting new benchmarks for oral therapies in autoimmune diseases. The coming years will reveal whether Icotyde can truly challenge the entrenched dominance of injectables like Skyrizi and solidify its position as a new blockbuster in the J&J portfolio.
Leave a Reply